Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a PRISM MedTech mover and industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024.
Ekso Bionics achieved record quarterly sales of $5.0 million in the second quarter of 2024, reflecting strong growth and significant progress in its operations. EKSO shares closed up 14% on Monday.
Key Highlights:
- Reported revenues of $5.0 million in the second quarter of 2024.
- Sold a total of 37 EksoHealth devices in the second quarter.
- Achieved a gross margin of 53% for the quarter ended June 30, 2024.
Scott Davis, Chief Executive Officer of Ekso Bionics said, “We are pleased with our significant progress in the second quarter of 2024, highlighted by record sales and the announcement of Centers for Medicare & Medicaid Services’ (“CMS”) national Medicare pricing determination for our Ekso Indego Personal device. With the Medicare reimbursement mechanisms in place, we are focused on reaching a larger U.S. population of individuals living with a spinal cord injury (“SCI”) and anticipate increased demand for Ekso Indego Personal in the second half of the year and longer term.”
About Ekso Bionics ®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
